Time filter

Source Type

Laffaire J.,Programme Cartes dIdentite des Tumeurs CIT | Stefano A.L.D.,AP HP | Stefano A.L.D.,French Institute of Health and Medical Research | Stefano A.L.D.,University Pierre and Marie Curie | And 35 more authors.
BioMed Research International | Year: 2014

Background. We performed a retrospective study to assess whether the initial molecular characteristics of glioblastomas (GBMs) were associated with the response to the bevacizumab/irinotecan chemotherapy regimen given at recurrence. Results. Comparison of the genomic and gene expression profiles of the responders (n=12) and nonresponders (n=13) demonstrated only slight differences and could not identify any robust biomarkers associated with the response. In contrast, a significant association was observed between GBMs molecular subtypes and response rates. GBMs assigned to molecular subtype IGS-18 and to classical subtype had a lower response rate than those assigned to other subtypes. In an independent series of 33 patients, neither EGFR amplification nor CDKN2A deletion (which are frequent in IGS-18 and classical GBMs) was significantly associated with the response rate, suggesting that these two alterations are unlikely to explain the lower response rate of these GBMs molecular subtypes. Conclusion. Despite its limited sample size, the present study suggests that comparing the initial molecular profiles of responders and nonresponders might not be an effective strategy to identify biomarkers of the response to bevacizumab given at recurrence. Yet it suggests that the response rate might differ among GBMs molecular subtypes. © 2014 Julien Laffaire et al. Source

Palozzo A.C.,Venetian Oncology Institute IRCCS | Di Turi R.,ASL Rome A
Nutritional Therapy and Metabolism | Year: 2011

Background: Decision makers in health care settings in Italy are often concerned about the costs of nutritional intervention. In the economic simulation performed in this paper, it is demonstrated how simple nutritional supplementation is more cost-effective than other therapeutic interventions provided by the Italian National Health Service (i.e., in oncology). Methods: In a review of efficacy studies in long-term nutrition, a paper published by Larsson in 1990 provided the basis for the cost-effective analysis of the actual work. Four hundred and forty-one elderly patients received an additional 400 Kcal/day to the normal spontaneous oral diet, via oral nutritional supplements or enteral nutrition. Results: After 6 months from the start, a statistically significant drop in mortality (from 18.6% to 8.6%) was observed in the subgroup of well-nourished patients supplemented at hospital admission. On the assumption that 6-month survivors were surviving for at least 6 months, an incremental cost analysis was performed. The sensitivity analysis showed the range of costs for each life year saved to be between €1,133 and €13,200, based on the less expensive product vs. the most expensive. © 2011 SINPE-GASAPE. Source

Cabibbo G.,University of Palermo | Tremosini S.,University of Barcelona | Galati G.,Biomedical University of Rome | Mazza G.,Civil Hospital of Brescia | And 4 more authors.
Expert Review of Anticancer Therapy | Year: 2014

Transarterial chemoembolization (TACE) is considered as the standard therapy for patients with intermediate-stage hepatocellular carcinoma. However, given the high heterogeneity of this population, no common strategy or protocol standardization has been defined yet. In the last few years TACE treatment has been combined with sorafenib systemic therapy, reporting overall positive results both in terms of safety and efficacy. This systematic review presents and critically discusses the evidence available on the use of TACE in combination (concomitant or sequential) with sorafenib, focusing also on clinical trials currently ongoing to better define an optimal therapeutic strategy for this group of patients. © 2014 Informa UK, Ltd. Source

Gillio-Tos A.,University of Turin | De Marco L.,University of Turin | Carozzi F.M.,ISPO Cancer Prevention and Research Institute | Del Mistro A.,Venetian Oncology Institute IRCCS | And 6 more authors.
Journal of Clinical Microbiology | Year: 2013

The Hybrid Capture 2 (HC2) test targets 13 human papillomavirus (HPV) types. Here, cross-reactivity with non-HC2-targeted HPV types is described. We aimed to define the proportion of HC2-positive women who had negative results with HC2-targeted HPV types and estimate its determinants and impact on women's health management. The New Technologies for Cervical Cancer (NTCC) trial was followed in two predetermined phases. Women in the experimental arm were tested for the presence of HPV DNA by HC2 following a sample collection in PreservCyt (first phase) or Digene specimen transport medium (STM) (second phase). HPV genotyping was performed on DNA samples from HC2-positive women by PCR with GP5+/GP6+ primers and reverse line blot (RLB) hybridization. Untyped samples were submitted to direct sequencing or restriction fragment length polymorphism. Multivariate logistic regression analysis estimated the adjusted odds ratios (ORs) between the presence of HC2-targeted types and age, viral load, and type of transport medium. Out of 2,920 HC2-positive samples, 2,310 (79.1%) were positive on RLB for HC2-targeted types, 396 were positive (13.6%) for only non-HC2-targeted types (mostly represented by HPV-53, HPV- 66, and HPV-70), and in 214 (7.33%) samples, no HPV types were detected. The probability of detecting HC2-targeted types increased with increasing viral load expressed as the relative light unit/positive-control specimen ratio (RLU/PC) (OR for unitary increase of log RLU/PC, 1.35; 95% confidence interval [CI], 1.30 to 1.42) and with STM versus PreservCyt (OR, 1.56; 95% CI, 1.25 to 1.84). If only the samples containing HC2-targeted types tested positive, the positive predictive value (PPV) would have increased from 7.0% (95% CI, 6.1% to 8.0%) to 8.4% (95% CI, 7.3 to 9.6), although 4.9% (95% CI, 2.4% to 8.8%) of cervical intraepithelial neoplasia grade 2+ (CIN2+) cases would have been missed. In conclusion, STM use and an increased cutoff would reduce the HC2 analytical false-positive rate and increase the positive predictive value for high-grade CIN. The gain in clinical sensitivity by detecting non-HC2-targeted HPV types is limited. Copyright © 2013, American Society for Microbiology. All Rights Reserved. Source

Bonanno L.,Venetian Oncology Institute IRCCS | Favaretto A.,Venetian Oncology Institute IRCCS | Rosell R.,Catalan Institute of Nanoscience and Nanotechnology
Anticancer Research | Year: 2014

The standard first-line treatment for around 80% of newly-diagnosed advanced non-small cell lung cancer (NSCLC) is chemotherapy. Currently, patients are allocated to chemotherapy on the basis of clinical conditions, comorbidities and histology. If feasible, platinum-based chemotherapy is considered as the most efficacious option. Due to the heterogeneity in terms of platinum-sensitivity among patients with NSCLC, great efforts have been made in order to identify molecular predictive markers of platinum resistance. Based on the mechanism of action of platinum, several components of DNA repair pathways have been investigated as potential predictive markers. The main DNA repair pathways involved in the repair of platinum-induced DNA damage are nucleotide excision repair and homologous recombination. The most studied potential predictive markers of platinum-sensitivity are Excision Repair Cross Complementing-1 (ERCC1) and Brest Cancer Type-I Susceptibility protein (BRCA1); however, increasing biological knowledge about DNA repair pathways suggests the potential clinical usefulness of integrated analysis of multiple DNA repair components. © 2014, International Institute of Anticancer Research. All rights reserved. Source

Discover hidden collaborations